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229 Abstract
30 A number of high profile revelations concerning anti-doping rule violations over the past 12 
31 months has outlined the importance of tackling prevailing challenges and reducing the 
32 limitations of the current anti-doping system. At this time, the necessity to enhance, expand 
33 and improve analytical test methods in response to the substances outlined in the World Anti-
34 Doping Agency’s (WADA) Prohibited List represents an increasingly crucial task for modern 
35 sports drug testing programs.  The ability to improve analytical testing methods often relies 
36 on the expedient application of novel information regarding superior target analytes for sports 
37 drug testing assays, drug elimination profiles, and alternative sample matrices, together with 
38 recent advances in instrumental developments. This annual banned-substance review 
39 evaluates literature published between October 2017 and September 2018 offering an in-depth 
40 evaluation of developments in these arenas and their potential application to substances 
41 reported in WADA’s 2018 Prohibited List.  
42
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355 Introduction
56 Drugs in sport and illicit means of performance enhancement have been referred to as one of 
57 sport’s greatest challenges in consideration of the irrevocably damaging effects of repeated 
58 drug scandals on professional sport’s reputation.1 The gravity of the situation was highlighted 
59 by discussions concerning the proposal to disregard athletics world records achieved prior to 
60 2005,2 the reported prevalence of (undetected) anti-doping rule violations (ADRVs),3-5 and 
61 the continuously growing scientific efforts towards a multifaceted understanding of doping,6, 7 
62 (potential) underlying mechanisms and incentives,8-10 as well as possible options of enhancing 
63 doping self-regulatory efficacy (whilst reducing moral disengagement in relation to doping)11 
64 and counteracting developments fueling trends towards doping activities.12-14 The widespread 
65 use of dietary supplements at all levels of sport15, 16 (despite the fact that supplementation may 
66 have limited value for some of the consumers)17 further complicates anti-doping efforts due to 
67 the still prevailing issue of contamination and adulteration.18, 19 Differentiating the intentional 
68 use of a doping agent from an inadvertent application e.g. through nutrition and/or dietary 
69 supplements or even prescription drugs, is a complex task and athletes as well as their 
70 entourage are advised to consider and minimize the risk of non-intentional doping before 
71 establishing respective supplementation programs,20 especially in the light of the World Anti-
72 Doping Agency’s (WADA’s) policy of strict liability.21 Also, ongoing changes in 
73 international legislations, e.g. concerning the status of cannabis,22, 23 do not simplify anti-
74 doping efforts. Based exclusively on analytical results that trigger the reporting of an adverse 
75 analytical finding (AAF) by the laboratory, the distinction of the deliberate clandestine use of 
76 doping agents from an unwitting administration or an unforeseen biotransformation of 
77 permitted drugs24 is difficult, and the complexity is further enhanced by individuals feigning 
78 an accidental uptake of a prohibited substance with the intention of mitigating potential 
79 sanctions.25, 26 Consequently, additional information of analytical/chemical nature as well as 
80 from complementary sources such as performance profiles have received growing attention, 
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481 and especially the concept of an “athlete’s performance passport” has been the subject of 
82 intense debate.27 Here (potential) benefits (e.g. possibility of identifying atypical changes in 
83 the athlete’s performance triggering target testing) as well as yet unresolved and unaddressed 
84 questions (e.g. accuracy and validity of collected performance data, environmental factors, 
85 etc.) have been discussed.28-32          
86 In continuation of previous editions,33 advances in and contributions to analytical means for 
87 human sports drug testing published over the past 12 months are evaluated in this annual 
88 banned-substance review, with a focus on substances and methods of doping as detailed in the 
89 WADA Prohibited List of 2018.34 The 2018 version of the Prohibited List was modified 
90 compared to the edition of 2017 and is now composed of only 11 classes of banned 
91 substances (S0 – S9 plus P1) and three categories of prohibited methods (M1 – M3) after 
92 “Alcohol” (formerly “P1”) was removed (Table 1). Additional major modifications to the 
93 Prohibited List concerned the reorganization of the category S2 (Peptide hormones, growth 
94 factors, related substances, and mimetics) with the concurrent removal of ARA290 and the 
95 addition of growth hormone fragments AOD-9604 and hGH 176-191, the addition of the Rev-
96 Erb α-agonist SR9009 to the category S4 (Hormone and metabolic modulators), and the 
97 removal of glycerol from the category S5 (Diuretics and masking agents). The monitoring 
98 program of 2018 continued to cover the in-competition use of the stimulants bupropion, 
99 caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine, and the 
100 narcotic analgesics codeine, hydrocodone and tramadol. Also, analyses concerning potential 
101 patterns of misuse regarding corticosteroids and any combination of beta-2-agonists were 
102 pursued in order to determine potential patterns of misuse and concurrent use of multiple 
103 drugs. A new addition to the monitoring program was 2-ethylsulfanyl-1H-benzimidazole 
104 (bemitil), determined in both samples collected in the events of in- and out-of-competition.35  
105 In this review, literature published between October 2017 and September 2018 has been 
106 evaluated (Table 2), which accounts for new and complementary sports drug testing 
Page 4 of 57
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5107 approaches advanced by enhanced analytical instrumentation and optimized target analyte 
108 selection. In addition, next generation multi-analyte test methods are featured,36-38 which have 
109 continued to represent preferred options for initial sample testing, and data obtained from 
110 confiscated products have necessitated increased vigilance concerning modified doping agents 
111 arguably designed to support the evasion of doped athletes.39 
112
113
114 Anabolic agents
115 Anabolic-androgenic steroids
116 The significant adverse effects of pseudo-endogenous and synthetic anabolic-androgenic 
117 steroid (AAS) misuse have been reported extensively in the past and continue to result in case 
118 reports of cardiovascular, renal, and hepatic issues plausibly correlated to AAS 
119 administration.40-42  Nevertheless, also in 2017, findings of AAS were top-listed in statistics 
120 regarding AAFs43 being one the most frequent reasons of drug-related anti-doping rule 
121 violations (ADRVs), and also on the level of recreational athletes the issue of AAS misuse 
122 has not been contained.44, 45   These aspects highlight the importance of continued investment 
123 into this specific field of anti-doping research, which supports efficient routine doping 
124 controls and, if indicated and requested, comprehensive clinical/toxicological analyses.46 
125
126 Initial testing procedures – comprehensive screening, metabolism studies & new target 
127 analytes
128 The quality of initial testing procedures (ITPs) is particularly critical for a comprehensive 
129 analytical spectrum in doping controls. Doping agents that are not spotted within the first 
130 screening instance are likely to remain undetected as no confirmatory analyses are triggered. 
131 Hence, improving the testing capability of ITPs by exploiting state-of-the-art technology and 
132 including the most representative target analytes is vital for upholding anti-doping regulations 
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6133 and counteracting athletes’ attempts of evading sports drug testing programs.47 In that context, 
134 the utility of a novel system composed of gas chromatography (GC) interfaced via electron 
135 ionization (EI) to a quadrupole-orbitrap mass analyzer was assessed.48 Following established 
136 urine sample preparation protocols including enzymatic hydrolysis, liquid-liquid extraction 
137 (LLE), and trimethylsilylation of the extracted analytes, a total of 40 AAS (including 
138 respective metabolites) plus three other anabolic agents were successfully determined. The 
139 mass spectrometer was operated simultaneously in full scan (m/z 100-700), targeted-SIM, and 
140 parallel reaction monitoring mode employing a mass resolution of 60,000 (full width at half 
141 maximum, FWHM). The continuous monitoring of lock masses ensured mass errors below 
142 1 ppm for all substances and corresponding minimum required performance levels (MRPLs)49 
143 were readily met by limits of detection ranging from 0.02 to 2.5 ng/mL. In comparison with 
144 low resolution mass spectrometry, the performance of the new platform was reported superior 
145 particularly for steroidal substances containing heteroatoms. Equal/competitive specificity 
146 and sensitivity was accomplished for substances composed of carbon, oxygen, and hydrogen 
147 only, suggesting that GC-high resolution/high accuracy mass spectrometry (HRMS) can 
148 contribute substantially to routine doping controls of anabolic agents, especially when 
149 considering the full MS dataset for retrospective reprocessing requests. The use of liquid 
150 chromatography (LC) combined with HRMS and MS/MS as ITP has been established and 
151 utilized since years, and the extent of compounds covered by this methodology has been 
152 constantly growing. Recently, Sardela et al. presented an assay allowing the screening of a 
153 total of 450 analytes in one analytical run, including 33 anabolic agents (or respective 
154 metabolites).36 Here, urine was subjected to enzymatic hydrolysis followed by weak cation 
155 exchange/mixed mode solid-phase extraction (SPE), and the extract was finally topped-up 
156 with diluted but otherwise untreated urine prior to injection into the LC-MS(/MS) system to 
157 include also conjugated metabolites and ionic compounds (such as meldonium) that are not 
158 easily extracted in urine via general approaches. Chromatographic separation of analytes was 
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7159 accomplished using a C-18 analytical column (50 x 2.1 mm, 1.7 µm particle size) and 
160 gradient elution was conducted using 5 mM ammonium formate (solvent A) and methanol 
161 (solvent B), both containing 0.1% formic acid. Scan-to-scan polarity switching ESI was 
162 employed and the MS was operated simultaneously in full scan mode (resolution 70,000), all-
163 ion fragmentation mode (resolution 17,500), and inclusion-list-controlled targeted MS/MS 
164 mode (resolution 17,500). Except for one metabolite of formebolone, the assay fulfilled all 
165 relevant MRPL criteria and proved fit-for-purpose for the doping control tests conducted at 
166 the Olympic Games 2016. 
167 In a comparable manner, Abushareeda et al. accomplished the implementation of 35 anabolic 
168 agents/metabolites into a multi-analyte ITP covering 304 target compounds.38 Also here, 
169 glucuronide conjugates were hydrolyzed, but instead of SPE-based concentration, 
170 deconjugated analytes were extracted by LLE. The organic layer was concentrated and 
171 topped-up with 20 µL of the native doping control urine sample. LC-MS(/MS) was conducted 
172 using a chromatographic system composed of a C-18 analytical column (100 x 2.1 mm, 1.8 
173 µm particle size) operated with 5 mM ammonium formate / 0.02% formic acid (solvent A) 
174 and acetonitrile/water (9:1, v/v) containing 5 mM ammonium formate / 0.01% formic acid 
175 (solvent B) using gradient elution. ESI and scan-to-scan polarity switching was used, and full 
176 MS (m/z 100-1000) as well as targeted MS/MS experiments (all conducted with a resolving 
177 power of 17,500) were employed to cover all analytes of interest. Besides the subset of AAS, 
178 which were detected at LODs sufficiently below respective MRPLs, also sulfoconjugated 
179 metabolites of testosterone (T), epitestosterone (E), 5α-dihydrotestosterone (DHT), 
180 dehydroepiandrosterone (DHEA), androsterone (A), and etiocholanolone (ETIO)  were 
181 determined in the same analytical run, thus enabling the supplementation of GC-MS-based 
182 steroid profile measurements.
183 The applicability of using nanoLC-HRMS to the direct analysis of diluted urine was discussed 
184 by Alcaranta-Duran et al.37 Following a 1:50 (v/v) dilution of urine, specimens were injected 
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8185 onto a nanoLC analytical column (150 x 0.075 mm, particle size 3 µm), and analytes were 
186 gradient-eluted using water (solvent A) and methanol (solvent B) both containing 0.1% 
187 formic acid. The mass spectrometer was operated in positive ionization mode with full scan 
188 (m/z 170 – 1000) and all-ion fragmentation settings, employing a resolution of 70,000 and 
189 15,000, respectively. The study demonstrated the successful inclusion of 8 AAS into a panel 
190 of 81 drugs, with LODs below WADA’s MRPL. However, in the light of the facts that only 
191 spiked samples were tested and (with the exemption of 19-norandrosterone) only intact drugs 
192 but no metabolites were analyzed, these data can only be considered as preliminary proof-of-
193 concept results and further investigations seem warranted, especially regarding the 
194 comprehensiveness of the approach and the robustness of the system. 
195
196 The outcome of the extensive reanalysis program of the Olympic Games in Beijing 2008 and 
197 London 201250 with over 100 additional AAFs can largely be attributed to advances in 
198 instrumentation and identification of new long-term metabolites of AAS, which highlights the 
199 relevance of in-depth investigations into the metabolism of AAS and corresponding studies 
200 concerning the identified metabolites’ structures. Such investigations are complex especially 
201 when the drugs of interest are not approved for human use, and options of surrogate models 
202 have been in great demand. One approach using zebrafish was recently reported,51 which 
203 demonstrated the principle ability of this model to produce human-like phase-I and phase-II 
204 metabolites of stanozolol. Here, phase-II metabolic products were of considerably lower 
205 abundance than phase-I metabolites but proof-of-concept data were obtained, motivating 
206 follow-up investigations. Subsequent to metabolite detection, full characterization of new 
207 target analytes is required, preferably by chemical synthesis and comparison of the synthetic 
208 products with metabolites observed in elimination study urine samples. Such syntheses and 
209 characterization studies were accomplished by Liu et al.52 and Forsdahl et al.53, 54 concerning 
210 long-term metabolites of dehydrochloromethyltestosterone. Especially the metabolite 
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9211 characterized as 4α-chloro-18-nor-17β-hydroxymethyl-17α-methyl-5α-androst-13-en-3a-ol 
212 (M3)53 has been shown to offer utmost retrospectivity concerning the administration of 
213 dehydrochloromethyltestosterone and methylclostebol, contributing to significant 
214 prolongations of detection windows. Similarly, the identification of new long-term 
215 metabolites concerning oxymesterone and mesterolone, namely 18-nor-17β-hydroxymethyl-
216 17α-methyl-4-hydroxyandrost-4,13-dien-3-one and 1α-methyl-5α-androstane-3,6,16-triol-17-
217 one, respectively, enabled a significant extension of the drugs’ detection windows. 
218 Metabolites were predicted in silico, and by means of highly sensitive GC-MS/MS analyses, 
219 their existence was eventually proven employing chemical ionization (CI) and tandem mass 
220 spectrometric characterization.55
221 Also, the role of bis-glucuronides as phase-II metabolites of AAS and their potential for 
222 doping control purposes was investigated.56 Eight isomers of androstane-3,17-diol, eight 
223 isomers of estrane-3,17-diol, two isomers of 5-androstene-3,17-diol, and 4-androstene-
224 3β,17β-diol were bis-glucuronidated and studied by LC-MS/MS in order to identify 
225 diagnostic collision-induced dissociation patterns, which were then applied to a 19-
226 norandrostenediol elimination study urine sample collected post-administration. The presence 
227 of a putative hydroxylated 19-norandrostenediol bis-glucuronide was reported and further 
228 studies into this group of target analytes was suggested.
229
230 Steroid profiling 
231 There is substantial value in the athlete biological passport (ABP) for various aspects of the 
232 global anti-doping program, and in this context of anabolic agents particularly the ABP’s 
233 steroid module. Hence, refining and optimizing this approach and identifying factors 
234 potentially influencing the steroid profile has been of great interest, which also expands to 
235 considerations regarding serum (reference) androgen concentrations,57 which are evidently 
236 affected particularly in elite endurance athletes.58 If and how this translates into altered 
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10
237 urinary steroid profiles remains to be demonstrated by future studies. Since a proportion of 
238 analytes included in the test spectrum of the steroid profile is of adrenal origin, Coll et al. 
239 investigated a possible impact of glucocorticoid administration on urinary steroid excretion.59 
240 A total of 40 study participants underwent systemic (oral/intramuscular) or topical 
241 glucocorticoid treatments with betamethasone, prednisolone, and triamcinolone acetonide at 
242 different dosages, and while excretion rates of steroid profile analytes were downregulated 
243 after systemic use of glucocorticoids, relative steroid profile parameters (T/E, A/T, A/ETIO, 
244 etc.) proved unaffected and robust. Similarly, hyperhydration was found to have influence 
245 neither on steroid profile data nor their interpretation.60 In a study with 7 males ingesting a 
246 single bolus of 20 mL of liquid per kg bodyweight, the expected effect on urinary specific 
247 gravity (SG) was observed, and adjustment to a reference value of the SG of 1.020 adequately 
248 ‘corrected’ for that aspect. SG was proven also superior to alternative measures for correction 
249 such as normalizing to creatinine. 
250 In contrast to glucocorticoids and hyperhydration, pregnancy was shown to have an impact on 
251 the athlete’s ABP.61 In an observational study including 67 pregnant women, significant 
252 alterations were observed with increased A/ETIO and 5α-androstanediol (5αAdiol) / 5β-
253 androstanediol (5βAdiol) ratios as well as a decrease in T/E, suggesting the consideration of 
254 pregnancy as a confounding factor of the steroidal module of the ABP. Disclosure and use of 
255 these kind of confidential and private data for result evaluation, is a topic to be discussed by 
256 ethical panels. Also, orally administered musk was reported to affect the urinary steroid 
257 profile as demonstrated in a comprehensive study conducted with 29 participants and musk 
258 specimens obtained from wild and domestic musk deer. Particularly the ratio of 5αAdiol / 
259 5βAdiol was influenced, and athletes should be made aware of the fact that products 
260 containing musk or musk extracts can result in AAFs in doping controls.62  
261
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262 Aiming at assessing the potential of additional target analytes contributing to routine steroid 
263 profiling, Esquivel et al. developed an LC-MS/MS-based method that allows quantifying 11 
264 endogenous steroid sulfates.63 In terms of steroid profiling, predominantly the fraction of 
265 glucuronic acid conjugates is currently considered, and little is known about the significance 
266 of corresponding sulfoconjugates in ant-doping analyses. Hence, a test method employing 
267 mixed-mode weak anion exchange SPE for urine extraction was established, and extracted 
268 phase-II metabolites were quantified using low resolution triple quadrupole (QqQ) LC-
269 MS/MS. The analytes were separated on a C-18 analytical column (2.1 x 100 mm, 1.8 µm 
270 particle size) and 5 mM ammonium formate (solvent A) and methanol (solvent B) as eluents, 
271 both containing 0.01% formic acid. The mass spectrometer was operated with scan-to-scan 
272 polarity switching and selected reaction monitoring (SRM), enabling the quantitation of 11 
273 sulfoconjugated steroids with limits of quantitation (LOQs) between 0.5 and 2 ng/mL. The 
274 approach was shown to allow complementing routine steroid profile analyses, but its utility in 
275 detecting clandestine administrations of pseudoendogenous steroids still needs to be shown by 
276 means of controlled elimination studies and comparison to inter- and/or intra-individual 
277 reference data. 
278 The fact that such studies supporting the development of doping control methods are vital for 
279 sports drug testing programs has been shown by Mullen et al. who assessed the capability of 
280 current routine approaches as well as experimental methods to uncover the administration of a 
281 single transdermal dose of T to 8 male study participants (including one individual exhibiting 
282 a double deletion of the UGT2B17 gene).64 The ABP allowed to detect the use of 100 mg of T 
283 in all subjects, with 5αAdiol/E being of noteworthy sensitivity followed by the parameters 
284 T/E and 5αAdiol/5βAdiol. Also hematological variables were affected such as reticulocyte 
285 count and percentage as well as serum T and DHT, while micro-RNA markers such as 
286 miRNA-122 were not found to be atypically altered. Hence, combining the information of 
287 different modules of the ABP might further enhance the utility of the testing approach, 
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288 triggering follow-up isotope ratio MS (IRMS) analyses. While IRMS was conducted on a 
289 subset of samples in this study, only two of them fulfilled WADA criteria for AAFs, 
290 indicating the limits of prevailing strategies.
291
292 Confirmatory testing procedures – isotope ratio mass spectrometry (IRMS)
293 The bottleneck of IRMS analyses, which has until today limited the use of this technology to 
294 confirmatory testing, has been the time-consuming sample preparation, limited batch size and 
295 extensive instrument run-times required for appropriate peak purities. Consequently, various 
296 studies were initiated aiming at accelerating the IRMS-based test methods to allow for more 
297 comprehensive sports drug testing programs concerning the misuse of 
298 natural/(pseudo)endogenous steroids. Tobias and Brenna assessed the utility of cryofocusing 
299 combined with fast gas chromatography and IRMS especially in the context of reduced 
300 analytical run times.65 A compartmentalized instrument consisting of a programmable 
301 temperature vaporization inlet and a GC allowing to operate two differently heated zones 
302 (with the first one containing a cold jet / hot jet unit for cryofocusing) was used. A 10 m ZB1-
303 ms analytical column (0.1 mm inner diameter, 0.1 µm film thickness) was installed and 
304 operated at 270°C allowing to separate the reference standards of A-acetate, 5βAdiol-
305 bisacetate, cholestane and 5β-pregnanediol-bisacetate at peak widths below 1 s (full width at 
306 half maximum, FWHM) in less than 6 min. While the applicability of the approach to 
307 authentic urine samples needs yet to be demonstrated, the proven option of shortening 
308 analytical run times by a factor of 3-4 without compromising analytical sensitivity is 
309 particularly promising.  
310 Having the same goal of higher sample throughput in IRMS testing in mind, de la Torre et al. 
311 suggested a simplified sample preparation protocol combined with a reduced spectrum of 
312 target compounds (TCs) and endogenous reference compounds (ERCs) as ITP.66 A volume of 
313 6 mL of urine was subjected to conventional LLE and enzymatic deconjugation procedures 
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314 followed by a modified LC fractionation protocol. Here, only two fractions were collected 
315 containing the TCs 5αAdiol and 5βAdiol (plus E) as well as the ERC 5α-pregnane-3α,20α-
316 diol (PD) within a shortened 22 min HPLC run, and only one GC/CIRMS analysis per urine 
317 sample was conducted specialized on measuring δ13C values of 5αAdiol, 5βAdiol, and PD. 
318 Consequently, the IRMS “screening” approach allowed an overall sample throughput of 30 
319 specimens / batch, and the method’s sensitivity (and fitness-for-purpose) was demonstrated by 
320 means of elimination study urine samples as well as routine doping controls analyzed with 
321 established confirmatory IRMS approaches and the newly presented ITP option. 
322 5αAdiol and 5βAdiol were also the TCs and PD and 5α-androst-16-en-3α-ol (16EN) the 
323 ERCs in an alternative ITP approach presented by Putz et al.67 Here, a reduction of manual 
324 workload and overall batch analysis time was accomplished by combining a modified sample 
325 preparation and the use of multidimensional (MD) GC/C/IRMS. Urine samples were solid-
326 phase extracted, liquid-liquid extracted, enzymatically hydrolyzed and again subjected to LLE 
327 prior to acetylation. Acetylated steroids were then fractionated by sequential elution from 
328 another SPE cartridge, and the obtained two fractions were concentrated and analyzed by 
329 MDGC/C/IRMS. In addition, the retained aqueous layer containing intact sulfoconjugates of 
330 steroids was treated with sulfatase, and the liberated phase-I metabolites were also recovered 
331 by an additional LLE. Hence, three fractions were obtained for analysis on a system 
332 consisting of two separate GCs, one equipped with a Optima 1 capillary column (30 m length, 
333 0.25 mm inner diameter, 1 µm film thickness) and the other equipped with a DB-17 MS 
334 capillary column (30 m length, 0.25 mm inner diameter, 0.25 µm film thickness), enabling the 
335 heartcutting of peaks of interest. The effluent was directed towards a quadrupole MS (for 
336 online peak purity and structure confirmation) as well as to the combustion interface/IRMS 
337 system. By means of omitting HPLC fractionation and shifting analyte purification towards 
338 automated MDGC, an ITP IRMS method was established that allowed reducing the overall 
339 sample preparation and analysis time (per batch) from two working days to one.   
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340 Independent from the employed analytical approach, detection windows for 
341 pseudoendogenous steroids strongly depend on the duration of the administered substances 
342 and their metabolites in human urine. A TC particularly suited for the determination of T, 4-
343 androstenedione, and DHT was identified with epiandrosterone sulfate (EPIAS), which 
344 proved competitive or even superior to other conventional TCs. As demonstrated by Piper et 
345 al., the confirmation of an exogenous carbon isotope signature was accomplished for a 
346 significantly prolonged period of time.68 EPIAS was recovered from urine as reported above 
347 by Putz et al.67 and determined using the newly established MDGC/C/IRMS approach. A 
348 depleted 13C/12C ratio was observed for 70 h, 130 h, and 240 h post-administration of 50 mg 
349 of DHT, 80 mg of 4-androstenedione, and 100 mg of epiandrosterone, respectively, 
350 demonstrating that especially the combination of optimized TC selection and instrumental 
351 setup can considerably improve routine analytical procedures.     
352
353 Other anabolic agents
354 Amongst other anabolic agents, the class of selective androgen receptor modulators (SARMs) 
355 has been found with constantly increasing frequency in doping control samples during the 
356 past 5 years,24 and a plethora of structurally SARM-related (and unrelated) products has been 
357 reported as being readily available through Internet-based providers.69 This is particularly 
358 interesting as clinical approval has still not been accomplished for any of the numerous 
359 SARM drug candidates currently being developed, despite favorable pharmacological and 
360 pharmacokinetic properties.70-72 Technically, SARMs are well covered by routinely applied 
361 analytical test methods in doping controls, with reported drug candidates being of low 
362 molecular mass nature with steroidal or non-steroidal core structures.73 However, information 
363 on mass spectrometric behavior and metabolism of these substances is an essential element in 
364 comprehensive anti-doping analytics. Hence, chemical syntheses of SARM drug candidates, 
365 in vitro / in vivo metabolism studies, and incorporation of diagnostic (product) ions into 
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366 routine doping controls are required. In this context, studies on collision-induced dissociation 
367 pathways of protonated/deprotonated molecules of the SARM drug candidates GSK2881078, 
368 PF-06260414, and TFM-4 AS (Figure 1)as well as EI-MS(/MS) fragmentation patterns were
369 presented, providing the basis for follow-up studies aiming at metabolite identification.74 
370 Especially the increasing availability of high resolution/high accuracy mass spectrometry 
371 hyphenated to both LC and GC systems and the concurrent option of all-ion fragmentation 
372 can support the testing for characteristic pharmacophores and, thus, indicate an administration 
373 of SARMs even in the absence of comprehensive data on human urinary metabolites.
374 A distinct challenge in sports drug testing that, despite various studies, has still not been 
375 addressed is the differentiation of clenbuterol originating from an inadvertent ingestion via 
376 meat contamination. A variety of analytical approaches potentially addressing the problem 
377 has been studied in the past, among which also the enantiomeric composition of clenbuterol in 
378 doping control urine samples was considered as a possible means to identify ‘animal-
379 processed’ clenbuterol in human urine. The significance of results obtained from these tests 
380 was however limited, although all investigated pharmaceutical clenbuterol formulations were 
381 found to exhibit racemic compositions,75 and case-by-case evaluations of AAFs are still 
382 required.   
383
384
385 Peptide hormones, growth factors, related substances and mimetics
386 Erythropoietin-receptor agonists
387 The impact of erythropoietic and non-erythropoietic effects of an illicit use of erythropoietin 
388 (EPO) and its derivatives on elite athletes’ performances has again been the subject of 
389 considerable debate. While empirical trials frequently corroborated positive effects of EPO on 
390 VO2max levels translating directly into increased maximum aerobic power, the question 
391 whether microdosed EPO can enhance an athlete’s sporting capabilities remained 
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392 unanswered.76 Irrespective, the need for improved test methods concerning the misuse of EPO 
393 and its analogs in sport has resulted in different studies aiming at expanding and fine tuning 
394 current strategies as well as exploring the value of alternative matrices and biomarker 
395 approaches.77 Desharnais et al. investigated the utility of immunopurifying serum/plasma and 
396 urine samples by means of streptavidin-coated magnetic nanoparticles in combination with a 
397 polyclonal biotinylated anti-EPO antibody, in order ensure appropriate qualities of 
398 electrophoretic analyses by omitting the necessity of time-consuming double blotting.78 The 
399 recovery of EPO, NESP, EPO-Fc, and CERA was found between 58 and 100% and serum 
400 LODs were between 4 and 8 pg/mL (NESP, EPO-Fc, and CERA) and 3.1 mIU/mL 
401 (recombinant human EPO BRP). Acceptance criteria for both SAR-PAGE as well as 
402 isoelectric focusing79 were readily met using this comparably low-cost immunopurification 
403 alternative. 
404 Focusing on EPO-Fc fusion proteins, Mesonszhnik et al. presented an LC-MS/MS-based test 
405 method, targeting peptidic structures of non-natural amino acid sequence composition 
406 originating from the fusion regions of EPO and the fragment crystallizable (Fc) portion.80 
407 Following an extensive bottom-up sequence characterization conducted with a variety of 
408 complementary peptidases, a potential target peptide obtained through Lys-C hydrolysis was 
409 identified. Proof-of-concept studies concerning the utility of the determined primary structure 
410 of the peptide for doping control purposes were performed by spiking blank serum with EPO-
411 Fc, which was processed by immunoaffinity purification, reduction and alkylation, followed 
412 by Lys-C hydrolysis and LC-MS/MS analysis. The employed instrument consisted of a C-18 
413 analytical column (2.1 x 100 mm, particle size 1.7 µm), and gradient elution with 0.1% formic 
414 acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B) was used to 
415 introduce the analyte into a QqQ-based MS system. The mass spectrometer was operated in 
416 positive ionization MRM mode, and two diagnostic precursor/product ion pairs were 
417 identified that were found specific for the fusion region-spanning peptide as no interfering 
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418 signal was found in blank serum sample analyses. While further figures of merit such as 
419 LOD, precision, etc. were not available, the method indicates another potential of desired MS-
420 based methods in the detection of erythropoiesis-stimulating agents (ESAs).
421 The option of using alternative matrices, here dried blood spots (DBS), for the analysis of 
422 EPO and its synthetic derivatives was explored by Reverter-Branchat et al.81 A single DBS 
423 was extracted extensively (4 h) into an aqueous buffer solution, which was then subjected to 
424 immunoaffinity purification (using an ELISA well plates coated with anti-EPO antibodies). 
425 Subsequently, established SAR-PAGE detection methods were applied, allowing for LODs 
426 per spot of 1.5 and 30 pg of recombinant EPO (rEPO) as well as NESP and CERA, 
427 respectively. The utility of the approach was further underlined by the analysis of rEPO 
428 administration study samples, collected after repeated administrations of 50 IU/kg, and 
429 specimens from patients having received NESP injections. The study demonstrated the 
430 traceability of rEPO in DBS for 48 h and NESP for at least 17 days, and detection windows 
431 for CERA were estimated with 16 days based on pharmacokinetic modeling and the assay’s 
432 LOD, corroborating the growing portfolio of applications for DBS in sports drug testing.
433 In the light of the complexity of EPO analyses in general and the desire of more global 
434 approaches allowing for capturing ESA-based doping attempts, it appears plausible that 
435 methods complementary to existing testing procedures are continuously being explored. One 
436 angle has been the investigation of transcriptome signatures that potentially indicate the use of 
437 erythropoietin-receptor agonists. Earlier studies with rEPO have identified transcriptional 
438 markers that were differentially regulated when compared to licit interventions such as high 
439 altitude training, and the applicability of these markers to scenarios of low-dose EPO use was 
440 assessed by Wang et al.82 This group studied 14 endurance-trained male athletes that received 
441 rEPO at 20-40 IU/kg, twice weekly over a period of 7 weeks and compared these to 25 
442 athletes exposed to high altitude and/or intense exercise. Candidate markers with promising 
443 sensitivity and specificity were identified with BCL2L1 and CSDA, which were suggested for 
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444 incorporation into future “–omics”-based strategies to uncover illicit manipulations of 
445 athletes’ erythropoietic system.
446
447 Hypoxia-inducible factor stabilizers and activators 
448 As an alternative therapeutic option to EPO, orally available prolyl hydroxylase inhibitors 
449 such as roxadustat, vadadustat, molidustat, etc. have been under development for several 
450 years, with few drug candidates being in advanced clinical trials. Despite the lack of full 
451 clinical approval, reports on AAFs have been issued for roxadustat and molidustat, which 
452 underlines the need for adequate test methods for hypoxia-inducible factor (HIF) stabilizers 
453 and activators in doping controls. In that context, Eichner et al. investigated the traceability of 
454 roxadustat and its main four metabolites (plus one photoisomer) in human urine and plasma 
455 following low- (0.3 mg/kg) and high-dose (4 mg/kg) drug administrations.83 Urine sample 
456 preparation for confirmatory analyses included the addition of stable isotope-labeled 
457 roxadustat and hydroxylated roxadustat sulfate as internal standards to 2 mL of each 
458 specimen, SPE, evaporation of the eluate, and reconstitution for LC-MS/MS analyses. 
459 Measurements were conducted using either a QqQ- or a Q orbitrap-based MS system 
460 hyphenated by ESI to LC equipped with a C-8 analytical column (3 x 50 mm, 2.6 µm particle 
461 size). Solvents used for gradient elution were 5 mM ammonium acetate (containing 1% acetic 
462 acid) and acetonitrile as solvents A and B, respectively. Due to the amphoteric nature of the 
463 target analytes, scan-to-scan polarity switching was employed, and LODs between 0.05 and 
464 0.1 ng/mL were accomplished. Plasma samples (0.5 mL), spiked with the same internal 
465 standards, were prepared by adding 1 mL of isopropanol followed by vigorous mixing and 
466 centrifugation. The supernatant was separated from the precipitate, evaporated, and 
467 reconstituted for LC-MS/MS analysis. Here, the analytical instrument consisted of a biphenyl 
468 analytical column (2.1 x 100 mm, particle size 2.7 µm), operated with 25 mM ammonium 
469 formate in 0.1% formic acid (solvent A) and acetonitrile (solvent B). Via ESI, the analytes 
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470 were introduced into a QqQ-based MS system, and by means of selected precursor/product 
471 ion pairs an LOD of 1 ng/mL was accomplished for all substances. These assays allowed to 
472 determine the use of low- and high-dose roxadustat administrations up to 96 and 167 h in 
473 plasma and serum, respectively, with roxadustat and its glucuronide as well as the 
474 sulfoconjugated and hydroxylated roxadustat as best target analytes.  
475 Testing for xenon in human plasma (or urine) has been conducted in sports drug testing since 
476 the prohibition of xenon in 2014. The impact of storage and freeze/thaw cycles on the xenon 
477 content in plasma was studied by Frampas et al.,84 who demonstrated that frozen conditions 
478 ensure the conservation of the analyte in plasma for up to 15 days. In contrast, storage at 
479 cooled or ambient temperatures resulted in losses of xenon between 60 and 98%, and also 
480 freeze/thaw cycles were found to negatively influence the analyte’s recovery. A limitation of 
481 this study however was that the spiking process of the samples involved puncturing of the 
482 sample vial septum, which might cause an increased analyte loss compared to samples with 
483 intact septa.
484
485 Transforming growth factor-beta (TGF-β) inhibitors
486 Due to the ability of members of the transforming growth factor-beta (TGF-β) superfamily to 
487 negatively regulate physiological processes such as erythropoiesis, substances like sotatercept 
488 and luspatercept (both representing fusion proteins composed of the Fc domain of human 
489 IgG1 and the extracellular part of the activin receptors type IIA and IIB, respectively) have 
490 been explicitly mentioned in WADA’s Prohibited List since 2017. Consequently, test 
491 methods for these advanced drug candidates have been required to sensitively analyze for 
492 their presence / absence in doping control blood samples, and due to their higher molecular 
493 mass properties (the homodimeric structure results in molecular masses > 100 kDa), 
494 especially immunological approaches have been favored. In comprehensive studies, Reichel 
495 et al. assessed the utility of strategies routinely available in doping control laboratories to 
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496 determine luspatercept85  and sotatercept86 in serum samples. A variety of options was tested 
497 for luspatercept including enzyme-linked immunosorbent assay (ELISA) and 
498 immunoprecipitation combined with isoelectric focusing (IEF) or SAR-PAGE and subsequent 
499 Western blotting. An ELISA was found to allow for sensitively detecting luspatercept while 
500 showing no cross-reactivity to sotatercept (LOD = 15.6 ng/mL), and a confirmatory testing 
501 procedure was established employing immunoprecipitation with a polyclonal antibody 
502 followed by SAR-PAGE and Western blotting utilizing a monoclonal detection antibody. 
503 Here, an LOD of 1 ng/mL was established, suggesting a particularly long detection window 
504 for luspatercept if administered in therapeutically relevant amounts. Similar strategies were 
505 pursued concerning sotatercept (also referred to ACE-011), but from a total of 27 available 
506 antibodies only four proved suitable for sports drug testing purposes and no commercial 
507 ELISA was found fit-for-purpose. The selected antibodies however enabled efficient 
508 immunoprecipitation and subsequent detection of sotatercept at serum concentrations as low 
509 as 0.1 ng/mL, and implementing analytes such as luspatercept as well as other TGF-β 
510 inhibitors generating a multi-analyte testing procedure appears feasible. It must be noted, 
511 though, that various different products and surrogate analytes, referred to as activin receptor 
512 fusion proteins, are available but exhibited considerably different affinities to the studied 
513 antibodies. In the absence of authentic post-administration samples and/or authentic drug 
514 candidate reference material, further tests are required to ensure appropriate testing 
515 capabilities of the developed methods for doping controls, also for similar products aiming at 
516 myostatin rather than activin (cf. Hormone and metabolic modulators).  
517
518
519 Growth hormone (GH), its fragments and releasing factors, and chorionic gonadotrophin 
520 (CG)
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521 Advancing the testing and detection capabilities concerning the misuse of GH and its 
522 releasing factors has continued to be of particular interest to doping control laboratories 
523 despite the fact that at least the extent to which GH itself possesses performance-enhancing 
524 properties is still unclear.87 The currently employed isoform test targeting the relative 
525 abundance of different GH variants in human serum has been model and template for a 
526 recently presented mass spectrometry-based approach, which complements routinely applied 
527 tests by providing quantitative information on serum concentrations of 22 kDa, 20 kDa, and 
528 “total” GH.88 Here, 500 µL of serum is enriched with 15N-labeled 22 kDa and 20 kDa GH as 
529 internal standards, and the entire specimen is subjected to enzymatic hydrolysis using 
530 activated trypsin. After centrifugation, the supernatant containing the diagnostic ‘signature’ 
531 peptides for either 22 kDa GH, 20 kDa GH, or “total” GH is HPLC-fractionated, and the 
532 obtained analytes are charge-derivatized with IPDOA-iodide and again purified by HPLC-
533 fractionation. Finally, both labeled and unlabeled GH peptides are analyzed using a 
534 chromatographic system equipped with a C-18 analytical column (2.1 x 250 mm, 3.6 µm 
535 particle size) and using 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic 
536 acid (solvent B). The eluate is directed via ESI to a linear ion trap/orbitrap instrument, 
537 operated in positive ionization and full scan/product ion scan mode. The approach allows for 
538 a limit of quantitation of 0.5 ng/mL, and particularly the ratio of 22 kDa / “total” GH proved 
539 informative concerning the presence of a non-natural isoform distribution in human serum. 
540 While being rather laborious and time consuming, the method could provide orthogonal 
541 information in cases of GH atypical or adverse analytical findings, especially in the light of 
542 recently reported GH products exhibiting an additional alanine residue at the N-terminus of 
543 the protein.39 
544 Modifications of illicit peptidic drugs, mostly by N-terminally added amino acid residues, 
545 have been reported also for the growth hormone releasing peptide (GHRP)-2, GHRP-6, and 
546 ipamorelin.39 Until the metabolism of these compounds is clarified, the structural alteration 
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547 needs to be taken into consideration in routine doping control test methods, such as the multi-
548 analyte procedure presented by Cuervo et al.89 A total of 15 peptidic drugs prohibited in 
549 sports, including GHRPs 1, 2, 4, 5 and 6 as well as relevant metabolites and alexamorelin, 
550 hexarelin, anamorelin and ipamorelin were determined from 1 mL of urine. Therefore, the 
551 sample was subjected to weak cation exchange SPE, followed by LC-MS/MS analysis. The 
552 LC was operated with water (solvent A) and acetonitrile (solvent B), both containing 0.2% 
553 formic acid, and gradient elution on a C-18 analytical column (2.1 x 50 mm, 2.7 µm particle 
554 size) allowed the separation of the target compounds prior to ESI-HRMS(/MS). The 
555 simultaneous acquisition of full MS and targeted MS/MS data provides the flexibility to 
556 incorporate additional peptidic drugs into the initial testing method, and with the current set of 
557 compounds, the assay allowed for LODs between 0.1 and 1.0 ng/mL, thus presenting a 
558 method fit-for-purpose in routine sports drug testing. Additional target analytes to consider 
559 would be GHRP-3 and its recently reported (in vitro generated) deamidated metabolite.90 The 
560 extension of existing assays to additional target analytes should however also consider 
561 differing adsorption effects of compounds as outlined by Judak et al. in a recent 
562 communication.91 In order to obtain adequate recoveries (and corresponding LODs), a careful 
563 characterization of test methods with regards to adsorption-related analyte losses is 
564 recommended.       
565 In order to efficiently complement immunological methods with mass spectrometric 
566 approaches concerning chorionic gonadotrophin (CG), the determination of urinary reference 
567 intervals using the MS-based assay were required. Butch et al. employed an established 
568 immunoextraction-LC-MS/MS-based method to quantify intact human CG (hCG), the free β-
569 subunit (hCGβ), and the hCGβ-subunit core fragment (hCGβcf), and by means of analyte 
570 concentrations determined in up to 570 male urine samples, upper reference limits were 
571 obtained that suggested a threshold concentration for intact hCG of 1.0 IU/L.92 While 
572 commonly a urinary threshold of 5 IU/L is applied when conventional immunoassays are used 
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573 in routine doping controls, the significantly lower values obtained using LC-MS/MS refer to a 
574 need for separate hCG thresholds depending on the analytical methodology. This has been 
575 considered in the corresponding WADA technical document insofar as a threshold of 2 IU/L 
576 has been set for LC-MS/MS-derived urinary hCG concentrations.93  
577
578
579 β2-Agonists
580 Anti-doping regulations regarding selected β2-agonists have been discussed extensively in 
581 2018, largely fueled by an AAF of salbutamol concerning the 2017 Tour de France winner,94, 
582 95 and the urinary thresholds especially for salbutamol has been questioned and debated.96, 97 
583 A growing body of evidence has been presented, corroborating that the systemic, high-dose 
584 administration of β2-agonists such as salbutamol and terbutaline does affect skeletal muscle 
585 protein turnover98, 99 thus, making tests for  misuse both justified and necessary. However, the 
586 currently enforced approach via urinary threshold levels has been criticized, supported by 
587 semi-physiological pharmacokinetic modeling, outlining the possibility of scenarios where 
588 athletes exceeding the established threshold values despite adherence to anti-doping 
589 regulations was demonstrated.96 The updated technical document regulating the determination 
590 of decision limits (TD2018DL) in anti-doping analyses notably addresses the issue of the 
591 influence of the specific gravity of a urine sample.100    
592 Higenamine is, in contrast to salbutamol and terbutaline, a comparably recent addition to 
593 WADA’s Prohibited List, and doping control test methods have been modified in order to 
594 include higenamine in routine initial testing procedures. In addition, studies into metabolites 
595 as potential target analytes were conducted, and the inclusion of the sulfoconjugate of 
596 higenamine was suggested based on findings in authentic doping control samples. Whilst not 
597 yet being fully characterized, the presence of higenamine sulfate in an athlete’s sample was 
Page 23 of 57
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24
598 confirmed by LC-MS/MS, offering a prolonged detection window for the prohibited 
599 substance that only constitutes an AAF if exceeding urinary concentrations of 10 ng/mL.101 
600 The natural occurrence of higenamine in traditional medicinal plants such as Nandina 
601 domestica, Aconitum charmichaelii, etc. has necessitated further investigations in an anti-
602 doping context to clarify whether the administration of over-the-counter products such as 
603 throat lozenges or dietary supplements can result in AAFs and thus in (inadvertent) anti-
604 doping rule violations. Okano et al. conducted an administration study with throat lozenges 
605 accounting for an oral administration of ca. 20 µg of higenamine.102 Urine samples collected 
606 up to 96 h were analyzed using a quantitative method for higenamine and its potential 
607 glucuronic acid conjugate(s). Urine samples were subjected to enzymatic hydrolysis followed 
608 by SPE, and the concentrated extract was subjected to LC-ESI-MS/MS analysis. 
609 Chromatographic separation was accomplished by means of a C-18 analytical column (100 x 
610 2.1 mm, particle size 1.8 µm) and mobile phases consisted of 0.1% formic acid (solvent A) 
611 and acetonitrile (solvent B). The QqQ was operated in MRM mode, and the overall LOD was 
612 0.02 ng/mL. Four male volunteers participated in the elimination study, and urinary 
613 concentrations of higenamine remained below 1 ng/mL, suggesting that at least the 
614 recommended use of the ingested product will not result in an AAF for higenamine. However, 
615 the aforementioned sulfoconjugated metabolite was not considered; i.e. a different sample 
616 preparation protocol that accounts also for higenamine sulfate could yield other/higher urinary 
617 concentrations for higenamine. Moreover, other products might contain larger amounts of 
618 (undeclared) higenamine and thus challenge the career of athletes.103
619
620 Hormone and metabolic modulators
621 The Prohibited List category of ‘hormone and metabolic modulators’ comprises of five sub-
622 categories and substances of particularly diverse physicochemical nature. Amongst these, 
623 aromatase inhibitors as well as selective estrogen receptor modulators (SERMs) and other 
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624 anti-estrogens were studied in particular concerning the possibility to test for their presence in 
625 human urine by means of antibody- or receptor-based assays. Keiler et al. investigated the 
626 binding properties and activation capability of the aromatase inhibitor formestane in a yeast 
627 cell-based androgen receptor assay.104 A significant activation was observed, opening 
628 potential applications of the assay towards urine testing, albeit the unequivocal presence and 
629 identity of any bound substance will still necessitate chromatographic/mass spectrometric 
630 methods. In a similar fashion, Salvador et al. assessed the utility of a prototype ELISA for 
631 monitoring main metabolites of the SERMs tamoxifen and toremifene as well as the anti-
632 estrogen clomiphene in human urine.105 The substantial similarity between the 4-hydroxylated 
633 target compounds  allowed to produce an antibody against their common motif, and the 
634 obtained antiserum was used to coat microtiter plates for the analysis of urine samples. Urine 
635 specimens need to be deconjugated by glucuronidase and sulfatase followed by LLE and 
636 concentration of the extract prior to application onto the ELISA plate. The obtained LODs of 
637 the assay were estimated between 150 and 630 pg/mL, thus readily meeting WADA’s MRPL 
638 for these analytes, although the same limitation as for the above discussed androgen receptor 
639 assay exists, i.e. eventual need of mass spectrometric confirmation. Further, whilst one of the 
640 objectives was to prepare a high-throughput approach, the need to hydrolyze and extract urine 
641 samples in combination with the limited number of target analytes covered reduces the 
642 method’s applicability to routine doping controls. It might however have an added value for 
643 targeted therapeutic drug monitoring.
644 The next subsection of the category of ‘hormone and metabolic modulators’ addresses 
645 substances such as myostatin inhibitors. This class of drug candidates is aimed at clinical 
646 treatment of muscle loss and weakness and a prominent representative of this group is 
647 bimagrumab, a monoclonal human anti-activin type II receptor (ActRII) antibody, which 
648 allows for blocking the myostatin-induced signaling cascade. In order to support doping 
649 control laboratories in testing antibody-based drugs enabling the down-regulation of 
Page 25 of 57
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26
650 myostatin effectivity, a method was established that includes IgG precipitation, affinity 
651 purification, enzymatic hydrolysis, and subsequent LC-MS/MS analysis.106 A volume of 200 
652 µL of serum was prepared for analysis using a stable isotope-labeled bimagrumab analog, and 
653 two pairs of diagnostic tryptic peptides were generated that allowed for the unequivocal 
654 detection of the drug candidate in clinical samples collected more than 4 weeks after the last 
655 drug administration. The employed chromatographs were either conventional or nanoflow 
656 LCs equipped with a C-18 analytical column with the dimensions of 50 x 3 mm or 100 x 
657 0.075 mm, respectively. Eluents used were water (solvent A) and acetonitrile (solvent B), 
658 both containing 0.1% formic acid. Further, either an ion mobility / TOF MS or an orbitrap MS 
659 were employed, to allow for LODs of 20 ng/mL of bimagrumab in human serum. The assay 
660 proved comparably time consuming and further experiments towards simplified initial testing 
661 options are warranted, while for confirmatory purposes, the reported method was found fit-
662 for-purpose.
663 Differentiating endogenously produced 5-aminoimidazole-4-carboxamide-1-β-D-
664 ribofuranoside (AICAR) from its synthetic analog has been accomplished by means of 
665 GC/C/IRMS in the past. An improved protocol was presented by Buisson et al., who modified 
666 the analyte purification strategy and further altered the derivatization step in order to promote 
667 the preferred formation of AICAR-tris-TMS.107 The selective trimethylsilylation of hydroxyl 
668 functions was accomplished by employing a derivatization mixture composed of MSTFA and 
669 imidazole in ethyl acetate, yielding robust and reproducible results allowing to determine 
670 carbon isotope ratios for AICAR and established ERCs. Further insights into the elimination 
671 characteristics of the metabolic modulator meldonium were presented by Forsdahl et al., who 
672 investigated the excretion profile of the prohibited drug following repeated intravenous 
673 administration.108 Established isotope-dilution LC-MS/MS approaches employing hydrophilic 
674 interaction liquid chromatography and QqQ-based detection were used to quantify urinary 
675 meldonium, and a three-compartment model for the drug’s pharmacokinetics was suggested. 
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676 With an assay LOQ of 10 ng/mL, meldonium was determined in participants’urine samples 
677 up to 162 days after receiving the last of three doses of 250 mg of meldonium. These findings 
678 further corroborate earlier observations of drug accumulation and retention in different bodily 
679 tissues, resulting in particularly long detection windows in routine doping controls. 
680
681 Diuretics and other masking agents, Stimulants, Narcotics, and Glucocorticoids
682 Modern analytical instruments as routinely applied in doping controls provide the necessary 
683 sensitivity and selectivity to unequivocally determine classes of prohibited substances 
684 including diuretics and other masking agents, stimulants and narcotics readily meeting 
685 WADA’s MRPL. Consequently, method optimization or new test assay developments are 
686 scarce concerning these doping agents; however, research concerning metabolism or factors 
687 potentially affecting urinary concentrations of these substances have been investigated as e.g. 
688 concerning the vasopressin receptor antagonist tolvaptan.109 In a comprehensive in vitro 
689 metabolism study, more than 20 phase-I metabolites of the diuretic agent were identified, with 
690 hydroxylated and carboxylated species either in unconjugated or glucuronidated form were 
691 suggested as ideal candidates for sports drug testing methods. The employed analytical 
692 strategy was based on LC-MS/MS using either QqQ or QTOF mass analyzers hyphenated via 
693 ESI to liquid chromatography. The study further underlined the impact drug-drug interactions 
694 and the corresponding influence of an individual’s medication as well as allelic variants on 
695 detection windows and urinary concentrations of the prohibited substances, which may 
696 become particularly important at the result-managing level. 
697 According to WADA’s 2017 Anti-Doping Testing Figures,43 substances classified as 
698 stimulants ranked 3rd amongst the most frequently detected prohibited compounds. Within the 
699 class of stimulants, methylphenidate was top-ranked with 108 reported occurrences 
700 worldwide in 2017; a noteworthy observation especially in the light of a recent study that 
701 indicates a reciprocal correlation of physical activity and the abundance of a performance-
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702 enhancing effect of methylphenidate110 that is often assigned also as a compound for 
703 therapeutic use exemptions (TUE) by the athletes. With regards to other stimulants, 
704 particularly the largely uncontrolled availability of selected substances such as octodrine111 or 
705 oxilofrine, octopamine, etc.112 has raised growing concerns as intended as well as 
706 unintentional anti-doping rule violations are facilitated.  
707 The above mentioned potential impact of drug-drug interactions on urinary elimination 
708 profiles of banned substances was also discussed in the context of the threshold substance 
709 morphine.113 Here, the effect of antifungals, benzodiazepines, and non-steroidal anti-
710 inflammatory drugs (NSAIDs) on the glucuronidation of morphine was studied in vitro, 
711 demonstrating a significant reduction of the abundance of morphine 3- and 6-glucuronide in 9 
712 out of 14 tested non-prohibited substances. Extrapolation of this observation to in vivo 
713 scenarios suggests a reduced renal elimination of total morphine, thus arguably lowering the 
714 urinary concentration that could potentially lead to an underestimation of the factual dose of 
715 morphine that the athlete was receiving. The traceability of another narcotic, oxycodone, and 
716 its main phase-I metabolites by means of blood/plasma and urine microsampling was 
717 investigated by Protti et al.114 Different matrices including DBS, dried plasma spots (DPS), 
718 dried urine spots (DUS) and volumetric absorptive microsampling (VAMS) specimens were 
719 prepared and LC-MS/MS assay characteristics were compared. Chromatography was 
720 accomplished by means of a C-18 analytical column (2.1 x 50 mm, particle size 3.5 µm), and 
721 gradient elution was employed using water and acetonitrile (both containing 0.1% formic 
722 acid). Following ESI, analytes were detected in MRM mode using a QqQ-based mass 
723 spectrometer. All matrices proved competitive to conventional samples concerning recovery, 
724 precision, and accuracy, and advantages were seen in storage requirements. However, the 
725 accomplished LODs and LOQs using microvolume samples were ca. 3-20-fold inferior in 
726 comparison to established plasma or urine sample preparation protocols, and especially for 
727 urine-based matrices, i.e. DUS and VAMS, also the aforementioned benefits of the sampling 
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728 devices appeared limited as conventional sample processing including enzymatic hydrolysis is 
729 required prior to generating the microvolume samples. Targeting the intact phase-II 
730 metabolites could be an alternative if appropriate reference material is available.
731 The urinary elimination profile of an orally administered dose of the glucocorticoid 
732 triamcinolone was studied by Chen et al., aiming at providing critical data for result 
733 interpretation and management since the use in sports is restricted to non-systemic routes of 
734 administration.115 The ingestion of 4 mg of triamcinolone resulted in urinary concentrations 
735 beyond the established reporting level of 30 ng/mL for more than 24 h in all volunteers (n = 
736 12), reaching up to mean peak concentrations of ca. 3200 ng/mL (2 h post administration). Of 
737 note, 12 and 20 mg of intra-tendinous injection of triamcinolone acetonide yielded peak 
738 urinary triamcinolone concentrations (2 h post administration) below 30 and 60 ng/mL, 
739 respectively, being relevant in the context of establishing plausibility between therapeutic use 
740 declarations and doping control analytical results. 
741
742
743 Manipulation of blood and blood components
744 The means to artificially increase an athlete’s red blood cell mass are commonly subsumed 
745 under the term “blood doping”, and a comprehensive review on the academic and sports-
746 related history of modifying the absolute amount of erythrocytes and erythropoiesis in general 
747 with particular focus on Olympic Games was recently published.116 An efficient anti-doping 
748 strategy enabling the detection of various ways of manipulating an individual’s blood 
749 composition towards enhanced athletic performance (including autologous and homologous 
750 blood transfusions, use of ESAs such as EPO, HIF stabilizers and activators, etc.) is based on 
751 the hematological module of the ABP. This module comprises (blood) volume-dependent 
752 parameters such as the hemoglobin concentration and, consequently, conditions and situations 
753 modulating the plasma volume are considered as confounding factors of the ABP.117, 118 
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754 Through a panel of plasma components including transferrin, albumin, creatinine, total 
755 protein and low-density lipoprotein, a model was constructed that enables estimating an 
756 athlete’s plasma volume, which allows accounting for plasma volume fluctuations. The 
757 implementation of this additional information into the hematological module of the ABP was 
758 shown to support the reduction of atypical passport findings, especially those flagging 
759 atypical hemoglobin concentrations.119 The continuous refinement of the ABP approach is of 
760 utmost importance and anticipated; its sensitivity regarding temporal changes in hematology 
761 caused by high-dose (6 x 250 IU/kg in 2 weeks) erythropoietin administrations followed by 
762 low-dose (9 x 10 IU/kg in 3 weeks) sustainment regimens was once more corroborated, 
763 suggesting an adequate performance for sports drug testing purposes.120 The influence of iron 
764 supplementation on the ABP particularly in the context of the athletes’ exposure to high 
765 altitude / hypoxia was investigated, demonstrating that ABP abnormalities can result from 
766 oral or intravenous iron supplementation. A total of 34 athletes was subjected to a 12-week 
767 study including a 5-week intervention period with 3 weeks of live-high / train-low scenarios 
768 where either placebo, daily oral iron supplementation, or three ferric carboxymaltose bolus 
769 injections were administered. Overall, non-systematic abnormalities were observed in all 
770 study groups, and iron supplementation affecting ABP parameters could not be excluded. 
771 Hence, information on altitude training and / or iron supplementation should be considered 
772 when interpreting ABP profiles.121
773 Complementing the ABP with additional information to support and facilitate profile 
774 interpretations has been of great interest, especially in order to account for the above-
775 mentioned environmental factors influencing the ABP. Potential marker candidates have been 
776 hepcidin, soluble transferrin receptor (sTFR), and ferritin, with sTFR and ferritin 
777 concentrations being particularly affected by blood withdrawal and hepcidin concentrations 
778 by blood transfusion. Information on these serum biomarkers concurrently determined with 
779 established ABP profile data have the potential to contribute to ABP readings as demonstrated 
Page 30 of 57
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
31
780 in a recent pilot study by Cox et al.122 An orthogonal approach to support the detection of 
781 autologous blood transfusion has been presented by Lamberti et al., who studied the relative 
782 abundances of different hemoglobin (Hb) variants in blood transfused individuals.123 Fetal Hb 
783 (HbF), HbA, HbA2, and glycated Hb (HbA1c) were determined from lysed erythrocytes 
784 using cation-exchange liquid chromatography and UV detection. A hemoglobin profile index 
785 was computed consisting of the product of HbA and HbA2 percentages divided by HbA1c, 
786 and alterations in the Hb profile were identified in post-withdrawal and post-transfusion blood 
787 samples of tested individuals. As the results are considered preliminary, further studies, 
788 especially intra-individual profiling, are deemed necessary to estimate the added value of this 
789 approach for anti-doping purposes.       
790 Another alternative test method relying on DBS rather than whole blood was presented by 
791 Cox et al., who determined the ratio of immature reticulocytes and red blood cells via their 
792 cell-specific proteins CD71 and Band3, respectively.124 In a pilot study, 15 participants 
793 underwent autologous blood transfusion, and CD71/Band3 ratios were compared to a saline 
794 transfused control group (n = 11). The approach proved capable of identifying 7 out of 10 
795 subjects receiving blood transfusion when applying a preliminary criterion of the 
796 CD71/Band3 ratio decrease from baseline, and further studies are warranted to determine the 
797 robustness of the assay, especially in the light of CD71 being potentially affected by acute 
798 infections. The combination of the CD71/Band3 ratio with other biomarkers, e.g. RNA-based 
799 parameters, was suggested, and Haberberger et al. presented a study on erythrocyte-derived 
800 microRNA (miRNA) that identified the upregulation of 6 miRNAs during erythrocyte storage 
801 as well as 22 miRNAs that were altered in the course of blood processing (filtration, addition 
802 of preservatives, centrifugation,  etc.).125 Whether these can be utilized as a biomarker 
803 signature for autologous blood transfusion needs to be verified in future studies that consider 
804 additional environmental factors potentially affecting miRNA expression.
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805 A different approach aiming at quantifying red blood cell microparticles (RBC-MPs) formed 
806 during storage of whole blood in conventional CPDA-1 blood bags was pursued by Voss et 
807 al.126 By means of flow cytometry, an increase of plasma-borne RBC-MPs (also referred to as 
808 microvesicles, exosomes, etc.) by a factor of 100 was observed 14 days after withdrawal 
809 under standardized storage conditions. In the absence of information on elimination kinetics 
810 of RBC-MPs in vivo, these results are considered preliminary but certainly add another 
811 optional biomarker to the portfolio of parameters supporting the interpretation of anti-doping 
812 analytical data. The potential of MPs to serve as biomarkers was supported by a similar 
813 investigation by Donati et al., suggesting the assessment of this parameter in future blood 
814 transfusion studies.127
815 While the aforementioned studies were all dedicated to the detection of blood transfusions, 
816 Marchand et al. focused on establishing and expanding test methods to include a new 
817 hemoglobin-based oxygen carrier (HBOC) derived from the marine invertebrate Arenicola 
818 marina.128 The macromolecular and cell-free hemoglobin exhibits a molecular mass of 3600 
819 kDa and was studied both in vitro by incubating human plasma with the drug candidate 
820 HemoxyCarrier (HC) as well as in vivo in a murine model.  Plasma was immunopurified and 
821 extracts were subjected to gel electrophoresis and Western blotting, outlining the principle 
822 traceability of the worm hemoglobin for 3 h post-injection. Extended detection windows are 
823 expected in the light of considerable plasma concentrations (reaching up to 5-15 mg/mL) and 
824 the option to target non-human globin-derived peptide sequences by mass spectrometry.  
825
826 Chemical and physical manipulation / gene doping
827 Evading detection of the use of prohibited substances or methods of doping has been 
828 attempted by chemical or physical manipulation of doping control samples in the past, some 
829 of which were identified predominantly by abnormal profiles observed in the steroidal module 
830 of the ABP.24 Whether or not ruthless individuals would consider irreversible orthopedic 
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831 interventions in expectation of gaining a competitive edge is yet unclear,129, 130 but the 
832 scenario cannot be fully excluded as the temptation to modify genetic material has been 
833 discussed also in the past.      
834 Extensive debates have continued around the topic of genetic predisposition as well as gene 
835 manipulation in sport, and rather different issues have been discussed with one calling into 
836 question the rules for who may compete in women’s sports,131 another addressing the 
837 relevance of genes and an athlete’s environment in an individual’s development from a 
838 talented athlete to a champion,132 and the necessity and means to monitor gene doping 
839 practices in elite sport.133 A variety of test methods targeting transgenic DNA in doping 
840 control samples have been established, largely relying on conventional PCR-based strategies. 
841 A potential alternative to these was suggested by Salamin et al., who discussed the utility of a 
842 loop-mediated isothermal amplification (LAMP) approach for routine doping controls. Being 
843 a rather recent complement to clinical analyses, no proof-of-concept data concerning its 
844 application in sports drug testing exists; however, as the underlying strategy appears 
845 compatible with existing approaches (utilizing primers that target synthetic exon/exon 
846 junctions of e.g. EPO cDNA), an additional tool might become available to support anti-
847 doping methods concerning future gene doping issues.133
848
849
850
851 Monitoring Program
852 The identification of potential patterns of misuse of substances currently not prohibited in 
853 sports is an important tool in anti-doping. Since 2012, nicotine has been among the analytes 
854 included in WADA’s monitoring program, fueled by controversial or incomplete data 
855 concerning the potentially existing ergogenic properties of the drug. To date, scientific data 
856 exists that in nicotine-naïve individuals, orally administered nicotine (2-5 mg) results in 
Page 33 of 57
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
34
857 enhanced anaerobic performance;134-136 however, since nicotine-naivety is hardly given in 
858 athletes that arguably use nicotine regularly to increase their physical performance, the 
859 question remains unanswered whether nicotine represents an issue for sports drug testing or 
860 rather for health protection.137, 138 Similarly, the analgesic agent tramadol was monitored since 
861 2012, and especially cyclists, who represented a sport discipline of substantial tramadol use, 
862 raised concerns about decreased awareness caused by tramadol.139 A recent study further 
863 outlined the potential of tramadol to increase performance in a 20-min time trial 
864 experiment,140 and the governing body of cycling, the Union Cycliste Internationale (UCI), 
865 decided to ban the use of tramadol in-competition from January 2019 onwards.141 
866 Phosphodiesterase type 5 (PDE5) inhibitors have not been the subject of WADA’s monitoring 
867 program so far. Anecdotal evidence exists that PDE5 inhibitors have been misused in sports 
868 for performance-enhancing purposes and several studies exist that suggest some potential to 
869 affect athletic performance as recently summarized by di Luigi et al.142 Yet, studies 
870 simulating conditions of elite level sport are missing and more information will be required.     
871
872
873 Conclusion
874 The process of updating, improving, and expanding analytical methods for doping control 
875 purposes has continued in 2017/2018, but also the relevance of factors potentially affecting 
876 test methods and corresponding results has, as in preceding years, been acknowledged. The 
877 emphasis of contributions published between October 2017 and September 2018 focused 
878 largely on anabolic agents, specifically on steroid profiling and accelerated isotope ratio mass 
879 spectrometry, allowing for increased numbers of routine doping controls being analyzed by 
880 IRMS. Also, a series of studies aiming at identifying new (bio)markers for blood doping 
881 practices were conducted, providing a substantial number of potential candidate analytes 
882 supporting the detection and/or corroboration of blood transfusions in particular. Further, the 
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883 use of modern analytical instruments (particularly mass spectrometers) in combination with 
884 newly characterized metabolites of peptide-derived drugs have been the subject of various 
885 publications. Key aspects of this annual banned-substance review are summarized in the Info 
886 Box in Figure 2.
887
888
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1360 Figure 2: Info box on particularly relevant observations
S1 • Phase-I long-term metabolites of dehydrochloromethyltestosterone were successfully synthesized,
corroborating metabolite identifications from elimination studies
• New phase-I long-term metabolites were identified for oxymesterone and mesterolone
• Routinely utilized steroid profile data are not affected by glucocorticoid treatments
• Pregnancy does affect steroid profile parameters, particularly by increasing A/ETIO and 5αDiol/5βDiol and
decreasing T/E ratios
• Combining steroidal module ABP data with hematological data and serum T and DHT concentrations enhances
the probability of detecting single transdermal doses of T
• Options of advanced / accelerated IRMS analyses were presented based on instrumental innovations and
sample preparation modifications
• A continuously increasing number of AAFs concerning SARMs has been recognized and new SARM candidates
were reported that warrant consideration in routine doping controls
S2 • Biotinylated anti-EPO antibodies allow for omitting double-blotting without compromising the test methods’
LODs
• Dried blood spots allow for testing recombinant EPO, NESP and CERA using established analytical methods
• The HIF stabilizer roxadustat is detected in blood and urine preferably as the intact drug and its glucuronide
• Test methods for the TGF-β decoy receptors  sotatercept and luspatercept were established based on
immunological and electrophoretic approaches
• A MS-based bottom-up method enabling antibody-free quantification of 22 kDa and ‘total’ GH was presented,
offering a complementary confirmatory approach to currently used immunological methods but still require
further proof-of-concept studies
S3 • Naturally occurring higenamine ingested in amounts of 20 µg (via lozenges) did not result in urinary
concentrations above the recommended reporting level
S4 • The anti-activin type II receptor antibody bimagrumab was successfully detected in post-administration serum
samples up to 4 weeks using LC-MS/MS-based approaches.
S5/S7 • Drug-drug interactions potentially affecting urinary concentrations of target analytes should be considered 
especially if threshold substances such as morphine are influenced in order to avoid underestimation 
M1 • Athletes total blood plasma volumes can be derived from a panel of plasma components, enabling the
accounting of plasma volume fluctuations in ABP readings
• Soluble transferrin receptor and ferritin concentrations as well as hepcidin have been corroborated as
potential biomarkers complementing the hematological module of the ABP
• Similarly, the relative abundance of Hb variants was found to serve as indicator of blood transfusions
• The ratio of CD71 and Band3 concentrations in DBS was found indicative for autologous transfusions through
significant deviations from individual baseline levels
• MicroRNA-derived markers as well as red blood cell microparticles might further contribute to detecting blood
transfusion practices
M3 • The clinical approach of loop-mediated isothermal amplification (LAMP) could provide a rapid means to
support determining transgenic DNA in doping controls
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